AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05942911
Drug: IHL-675A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination product containing CBD and HCQ UniGel™ technology by ProCaps®. IHL-675A consists of a solid, film coated HCQ tablet that is contained within a CBD oil solution gel cap. Each IHL-675A gel cap contains 75 mg of CBD and 100 mg HCQ.
Trial: NCT05942911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated using UniGel™ technology by ProCaps®. The soft gel capsules contain the inactive ingredients of the IHL-675A capsules and no active ingredients. These capsules look identical to the IHL-675A UniGel™ capsules to aid double-blinding.
Trial: NCT05554237
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06066060
Drug: JMKX000623
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMKX000623, administered orally ;
Trial: NCT05061251
Drug: BAY 2402234
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
Trial: NCT06110923
Drug: D091
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once administration of Investigational Product per day
Trial: NCT02590523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral placebo injection with BSS during cataract surgery
Trial: NCT06049290
Drug: LBL-034 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose - MTD; Q2W; intravenous infusion
Trial: NCT05371184
Drug: L-Glutamine, Oral Powder for Reconstitution
RxNorm normalized name: L-Glutamine, oral powder for reconstitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine is an essential amino acid. It will be provided in a powder form. It will be dissolved in at least 8 ounces of hot or cold liquid. It can also be mixed with a soft food such as pudding, applesauce, or yogurt. Then it will be Stirred and then eaten or drunken The Glutamine will be as an add on to the Standard of care
Trial: NCT04838743
Drug: IDegLira
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study.
Trial: NCT05967520
Drug: JMKX000189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JMKX000189 will be administered orally once a day
Trial: NCT05967520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once a day
Trial: NCT00000875
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04841720
Drug: HSK16149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 capsules for single use: D1-D4 oral HSK16149 capsules 80 mg BID, D5 only oral HSK16149 capsules 80 mg in the morning on an empty stomach; wash-out period is about 4 days (D5-D8);
Trial: NCT05242445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via SC injection or as an IV infusion.
Trial: NCT06373042
Drug: Intraarterial and intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial and intravenous placebo after endovascular thrombectomy
Trial: NCT05027516
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection + single dose of azithromycin 2g orally
Trial: NCT03097796
Drug: PUL-042
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUL-042 Inhalation Solution
Trial: NCT05398393
Drug: lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
Trial: NCT05734794
Drug: Steroid
RxNorm normalized name: Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks. Vitamin D and calcium(adjusted according to the blood calcium level) were administered for three months.
Trial: NCT06369350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule will be given for up to 31 days.
Trial: NCT05860699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo made by the same manufacturer to look like the active pills
Trial: NCT05860699
Drug: Half dose CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 10 days during their inpatient stay
Trial: NCT05860699
Drug: Full dose CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 10 days during their inpatient stay
Trial: NCT05290558
Drug: Placebo Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the ingredients: grounded black rice and permitted colouring. The ingredients are encapsulated within a gelatine capsule.~Dosage of the study drug is as follows: 3 pills each time, for 3 times a day, taken for 6 days every week for 1 year
Trial: NCT04927572
Drug: FMX114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT06365515
Drug: Levodopa administration
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To boost dopamine levels 150mg/37.5 mg L-DOPA/benserazide will be administered in line with recent studies (Kroemer et al., 2019). Maximum plasma concentration of Madopar occur \~60 minutes after drug administration. Participants will start the Effort Allocation Task 45 minutes after Levodopa administration.
Trial: NCT06365515
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered as the placebo-controlled condition.
Trial: NCT06170827
Drug: AIO-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIO-001 Solution for SC injection.
Trial: NCT05450458
Drug: KNEE JOINT INFILTRATION WITH HYALURONIC ACID WITH SORBITOL SYNOLIS VA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KNEE INFILTRATION WITH HYALURONIC ACID WITH SORBITOL IN SPORTSMEN
Trial: NCT06734702
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks for 2 cycles.
Trial: NCT00987233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Trial: NCT05247996
Drug: Multi-target Drug Therapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-target drugs (lenvatinib or donafenib) are selected at the patient's preference. Oral multitarget drugs are initiated 3-7 days after initial TACE treatment until tumor progression is assessed. The initial dose of lenvatinib is 8mg/ day (bodyweight \< 60 kg) or 12 mg/ day (body weight≥60 kg); Donafenil 0.2g, twice a day, taken orally on an empty stomach. If the medication is missed, there is no need to take a refill and the next dose shall be taken at the usual time.
Trial: NCT05247996
Drug: Immunocheckpoint Inhibitor Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection. Treatment shall be based on the immune checkpoint inhibitors before enrollment, and it is not recommended to change the immune checkpoint inhibitors; Dosage: 200mg, iv, D1, every 21 days (Q3W), continuous until tumor progression.
Trial: NCT04798976
Drug: neoadjuvant/adjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy/endocrine therapy/surgery/radiotherapy
Trial: NCT05674422
Drug: total neoadjuvant therapy
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be aged 18 years or older, with histologically confirmed rectal adenocarcinoma, located in the mid or distal third (with the inferior margin within 12cm from the anal verge), clinically staged II and III (cT3-T4 and/or any TN+), scheduled to undergo TNT will be eligible. All cases and treatment decisions will be discussed by local Multidisciplinary Boards
Trial: NCT05119920
Drug: Placebo Ophthalmic Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Ophthalmic Topical Cream
Trial: NCT04914741
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Trial: NCT04914741
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50mg/m\^2 administered by IV infusion on Day 1 of every 21-day cycle
Trial: NCT04914741
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 100mg orally on Days 1-5 of every 21-day cycle
Trial: NCT05657704
Drug: The patients in experimental group will be genotyped before surgery and treatment will be prescribed according to the CYP2D6 phenotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be prescribed according to the CYP2D6 phenotype. Normal Metabolizers (NM): Tramadol 100 mg every 8 hour; Ultrarapid Metabolizers (UM): Tramadol 50 mg every 8 hours Intermediate and poor metabolizers (IM/PM): dexketoprofen 25 mg every 8 hours
Trial: NCT04976738
Drug: Cybis™ 10:25 THC:CBD oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cybis™ 10:25 containing 10 mg/mL of D9-THC and 25 mg/mL of CBD, formulated in medium chain triglycerides (MCT)
Trial: NCT06451172
Drug: ASO
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
Trial: NCT05510843
Drug: THB001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg capsules for oral administration
Trial: NCT05889351
Drug: Vehicle gel, 4 + 4 applications or 4 + 2 applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control arm/placebo
Trial: NCT06385808
Drug: MTBF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be treated with mitoxantrone hydrochloride liposome combined with thiotepa, busulfan and fludarabine as conditioning regimen prior to allo-HSCT.~Mitoxantrone hydrochloride liposome 24mg/m\^2 ivgtt d-7; Ctepide 5mg/kg ivgtt d-6\~-5; Busulfan 0.8mg/kg q6h ivgtt d-4\~-2; Fludarabine 50mg/m\^2 ivgtt d-4\~-2.
Trial: NCT04734210
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical vehicle solution
Trial: NCT06580678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application of Water for Injection
Trial: NCT05046795
Drug: Placebo inhalation solution QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06331884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of placebo
Trial: NCT04535401
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04535401
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002434
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05102396
Drug: Topical placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive topical placebo spray.
Trial: NCT05430711
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After randomization, participants will receive dinoprostone 10 mg vaginal delivery system which will remain in place up to 24 hours or until the labour begins. At the onset of labor or after 24h it will be removed and participant transferred to labour room for further standard procedures.
Trial: NCT05265130
Drug: YiQiFuMai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YQFM is a redeveloped preparation based on the traditional Chinese medicine formula Sheng-Mai-San, which is widely used in clinical practice in China, mainly for the microcirculatory disturbance-related diseases.
Trial: NCT05265130
Drug: 0.9% Normal Saline 250ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline 250ml IV, about 40 drops per min.
Trial: NCT06553950
Drug: Mandibular stabilization splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated by mandibular stabilization splint and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.
Trial: NCT05739877
Drug: DA-1229_01 2.5/500mg (Before)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05739877
Drug: DA-1229_01 2.5/500mg (After)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT04371952
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of doxycycline 200 mg/day to placebo
Trial: NCT04371952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo : lactose, 380 mg/gélule
Trial: NCT06167187
Drug: Ketorolac and fentanyl
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
Trial: NCT05356741
Drug: AMX-818
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as IV infusion
Trial: NCT00000643
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05003089
Drug: BAY1834845
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT05003089
Drug: BAY1830839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT05003089
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT05003089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral.
Trial: NCT06066203
Drug: GNC-035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GNC-035 was administered by intravenous infusion for 2 h-4 h, once a week ( IV, QW ), 3 weeks as a cycle.
Trial: NCT06433518
Drug: recombinant hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.~Control Group: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.~All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.~The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.~Primary and secondary outcomes will be compared between the two groups.
Trial: NCT05783193
Drug: TGIR (Traditional Gastrointestinal Remedy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGIR botanical formulation
Trial: NCT05783193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT04521335
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
Trial: NCT05902819
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
Trial: NCT05902819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.
Trial: NCT04900038
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 was available as 25 mg or 100 mg tablets administered orally.
Trial: NCT04847518
Drug: Kan Jang capsules
RxNorm normalized name: ASIAN GINSENG 500 mg in 500 mg ORAL CAPSULE [Cheong-Kwan-Jang Korean HongSam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule contains a fixed combination of proprietary~* Andrographis paniculata Nees. herb, native extract, DER native 4,5-8,0 :1 260 mg (Diterpene lactones andrographolide and 14-deoxy, 11,12- didehydroadnrograholide) 15-20 mg~* Eleutherococcus senticosus (Rupr. et Maxim) Harms, root, native extract DER native 17-30:1 : 11.4 mg and other inactive excipients (Polycristalline cellulose, Magnesium stearate).
Trial: NCT05080959
Drug: Naropin 150 MG Per 20 ML Injection
RxNorm normalized name: Naropin 150 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose
Trial: NCT05080959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose
Trial: NCT05907993
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Ibuprofen versus intravenous Ketorolac for postoperative pain relief
Trial: NCT05355974
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine continuous infusion at 0.10 mcg/kg/min
Trial: NCT05355974
Drug: Lactated Ringers, Intravenous
RxNorm normalized name: Lactated Ringers, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL infusion run at 999mL/hr
Trial: NCT05355974
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL infusion run at 999mL/hr
Trial: NCT05355974
Drug: Plasma-lyte
RxNorm normalized name: Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL infusion run at 999mL/hr
Trial: NCT02649530
Drug: WNT974
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04883658
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04339270
Drug: Azithropycin according to symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the standardized comparator arm will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers).~CASA-Q will be evaluated every 3 months.~* If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70.~* If the patient has a sputum symptoms score\> 70, management is not changed.
Trial: NCT06644573
Drug: Diprivan (propofol), Astra-Zeneca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprivan/Propofol is a short-acting intravenous anesthetic used in PROSOMNIA Sleep Therapy to induce rapid and controlled REM sleep. Unlike other sleep aids, Propofol works by potentiating GABA_A receptor activity, leading to a deeper and faster transition into sleep. The administration is closely monitored in real-time using EEG to ensure optimal sleep stages are achieved. Propofol is distinct from traditional sedatives due to its precise control, rapid onset, and ability to clear adenosine from the brain, reducing sleep pressure effectively and safely.